Home » Newsletters » BioWorld Asia

BioWorld Asia

June 14, 2000

View Archived Issues

European Biotech Fund Raising Lags, But Products Are Coming

Canada Invests In Virtual Medical Health Institutes

GenOdyssee Gathers $8.6M In Financing For SNP Effort

Taiwan Firm Invests $6.2 Million In Progen For Molecule Development

Peptide Therapeutics Has Positive Results In Phase III Arilvax Trial

Oxford, Aventis Extend Agreement In Cardiovascular Gene Therapy

British Biotech Pares 80 Jobs, With Saved Funds To Push Development

Scotia Gets Boost From Journal Backtracking On Foscan Data

European Industrialists Call For More Backing For Biotech

Transghne Receives $1 Million Milestone from Schering-Plough

ProChon, MorphoSys Form Deal Around Antibody Library

Genset Raises EUR49 Million In Private Placement Of Bonds

ICH Mulls Gene Therapy Rules, Common Application Format

Other News To Note

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...